tetano
Editor, Senior Moderator
Expert Rev Vaccines. 2016 May 21. [Epub ahead of print]
[h=1]Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial.[/h] Mutsaerts E[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Madhi SA[SUP]1,[/SUP][SUP]2,[/SUP][SUP]4[/SUP], Cutland CL[SUP]1,[/SUP][SUP]2[/SUP], Jones S[SUP]1,[/SUP][SUP]2[/SUP], Hugo A[SUP]1,[/SUP][SUP]2[/SUP], Trenor S[SUP]1,[/SUP][SUP]2[/SUP], Treurnicht FK[SUP]4[/SUP], Klipstein-Grobusch K[SUP]3,[/SUP][SUP]5[/SUP], Weinberg A[SUP]6[/SUP], Nunes MC[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] We assessed the persistence of hemagglutinin inhibition (HAI) antibodies and the vaccine efficacy (VE) of trivalent inactivated influenza vaccine (IIV3) following vaccination of a cohort of pregnant South African women during a second influenza season.
[h=4]METHODS:[/h] A cohort of w omen, who participated in a randomized placebo-controlled trial on the safety, immunogenicity and efficacy of IIV3 in 2011 had HAI titers measured in 2012 and were monitored for influenza illness until the end of 2012.
[h=4]RESULTS:[/h] The proportion of women with HAI titers ≥1:40 was significantly greater in vaccinees (63%) compared to placebo-recipients (22%; p<0.001). VE in 2012 was 63.8% (95% confidence interval [95%CI]: -33.7%, 90.2%); combined VE for 2011 and 2012 was 58.3% (95%CI: 0.2%, 82.6%).
[h=4]CONCLUSIONS:[/h] The majority of women who received IIV3 during pregnancy had HAI titers above the putative threshold for protection against influenza illness one year after vaccination and showed a trend towards protection against influenza disease.
[h=4]KEYWORDS:[/h] efficacy; immunogenicity; influenza vaccine; maternal immunization
PMID: 27212228 [PubMed - as supplied by publisher]
[h=1]Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial.[/h] Mutsaerts E[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Madhi SA[SUP]1,[/SUP][SUP]2,[/SUP][SUP]4[/SUP], Cutland CL[SUP]1,[/SUP][SUP]2[/SUP], Jones S[SUP]1,[/SUP][SUP]2[/SUP], Hugo A[SUP]1,[/SUP][SUP]2[/SUP], Trenor S[SUP]1,[/SUP][SUP]2[/SUP], Treurnicht FK[SUP]4[/SUP], Klipstein-Grobusch K[SUP]3,[/SUP][SUP]5[/SUP], Weinberg A[SUP]6[/SUP], Nunes MC[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] We assessed the persistence of hemagglutinin inhibition (HAI) antibodies and the vaccine efficacy (VE) of trivalent inactivated influenza vaccine (IIV3) following vaccination of a cohort of pregnant South African women during a second influenza season.
[h=4]METHODS:[/h] A cohort of w omen, who participated in a randomized placebo-controlled trial on the safety, immunogenicity and efficacy of IIV3 in 2011 had HAI titers measured in 2012 and were monitored for influenza illness until the end of 2012.
[h=4]RESULTS:[/h] The proportion of women with HAI titers ≥1:40 was significantly greater in vaccinees (63%) compared to placebo-recipients (22%; p<0.001). VE in 2012 was 63.8% (95% confidence interval [95%CI]: -33.7%, 90.2%); combined VE for 2011 and 2012 was 58.3% (95%CI: 0.2%, 82.6%).
[h=4]CONCLUSIONS:[/h] The majority of women who received IIV3 during pregnancy had HAI titers above the putative threshold for protection against influenza illness one year after vaccination and showed a trend towards protection against influenza disease.
[h=4]KEYWORDS:[/h] efficacy; immunogenicity; influenza vaccine; maternal immunization
PMID: 27212228 [PubMed - as supplied by publisher]